Benaroya Research Institute Praises the Results of a Teplizumab-based Clinical Trial as it can Delay Onset of Type 1 Diabetes

Benaroya Research Institute Praises the Results of a Teplizumab-based Clinical Trial as it can Delay Onset of Type 1 Diabetes

A new global study reveals that an immunotherapy drug called┬áteplizumab┬ácan delay the onset of Type 1 diabetes for at least two years in high-risk kids and adults, according to the results of a recent study with 28 research sites. Recently reported in WNDU 16...

Pin It on Pinterest